TAGRISSO® (osimertinib) demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated ...
Nearly three in four patients treated with adjuvant TAGRISSO were alive and disease-free at four years Exploratory results showed TAGRISSO also reduced the risk of disease recurrence in the brain or spinal cord by 76% in patients with Stage II-IIIA disease …